Literature DB >> 3257590

Preoperative lymphocyte subsets and infectious complications after colorectal cancer surgery.

P I Tartter1.   

Abstract

Peripheral lymphocytes, T cells, and T cell subsets of 141 consecutive patients with colorectal cancer were measured preoperatively to determine whether infectious complications could be predicted from derangements of T cell subsets. T cell subset abnormalities reportedly precede sepsis in patients with burn injuries. All patients received preoperative bowel preparation with laxatives, enemas, oral neomycin and erythromycin base, and intravenous cefazolin. Eighteen (13%) of the 141 patients had infectious complications and these complications accounted for two deaths. The variables of age, sex, tumor location, admission hematocrit, white blood count, lymphocytes, T cells (Leu-1), helper cells (Leu-3), suppressor cells (Leu-2), natural killer cells (Leu-7), operative blood loss, procedure, specimen length, duration of surgery, tumor size, tumor differentiation, nodal status, and Dukes' staging were not significantly (p greater than 0.05) related to the development of infectious complications. These results indicate that preoperative evaluation of T cell subsets in patients with colorectal cancer is not useful for predicting postoperative septic complications.

Entities:  

Mesh:

Year:  1988        PMID: 3257590

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  2 in total

1.  Perioperative restricted fluid therapy preserves immunological function in patients with colorectal cancer.

Authors:  Hong-Ying Jie; Ji-Lu Ye; Hai-Hua Zhou; Yun-Xiang Li
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

2.  Different immune responses to abdominal surgery in men and women.

Authors:  Matthias W Wichmann; Christian Müller; Günther Meyer; Michaela Adam; Martin K Angele; Simone J Eisenmenger; Friedrich-Wilhelm Schildberg
Journal:  Langenbecks Arch Surg       Date:  2003-01-14       Impact factor: 3.445

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.